浙江博锐生物制药股份有限公司

FAMEGLOW

TJCD

ZHONGSHENJIANYE

NEW GONOW RV

51WORLD

ZXZN QI-HOUSE

EASYHOLD GROUP

INTELLIMARK W27

CH CITY INFRA

GREEN BROAD

科兴生物制药股份有限公司

<p>Chongqing Claruvis Pharmaceutical Co., Ltd. has received marketing approval from China's National Medical Products Administration for Retoxin®, the world's first recombinant botulinum toxin type A. This innovative drug offers a safer and more effective treatment for moderate-to-severe glabellar lines and is also being developed for adult upper limb spasticity. The approval marks a significant technological advancement in botulinum toxin therapy, transitioning from traditional extraction methods to precision-engineered recombinant production. Claruvis aims to expand its pipeline of recombinant products for various neurological and aesthetic applications.</p>

prnewswire

08:38 ETWorld's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

浙江博锐生物制药股份有限公司(N26016.HK)

08:38 ETWorld's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical